Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S14, June 2016

Systemic Autologous Mesenchymal Stem Cell Therapy for Immunomodulation in Resistant Myasthenia Gravis

      Background: Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disease characterized by skeletal muscle weakness which improves after rest. MG is caused by a defect in the neuromuscular transmission caused by antibodies which block, attenuate, or destroy acetylcholine receptors preventing muscle contraction.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect